Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 9, 2020
- Accepted in final form August 24, 2020
- First Published October 12, 2020.
Article Versions
- Previous version (October 12, 2020 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Takao Hoshino, MD,
- Shinichiro Uchiyama, MD,
- Lawrence K.S. Wong, MD,
- Kazuo Kitagawa, MD,
- Hugo Charles, BST,
- Julien Labreuche, BST,
- Philippa C. Lavallée, MD,
- Gregory W. Albers, MD,
- Louis R. Caplan, MD,
- Geoffrey A. Donnan, MD,
- José M. Ferro, MD,
- Michael G. Hennerici, MD,
- Carlos Molina, MD,
- Peter M. Rothwell, MD,
- P. Gabriel Steg, MD,
- Pierre-Jean Touboul, MD,
- Éric Vicaut, MD,
- Pierre Amarenco, MD;
- on behalf of the TIA registry.org Investigators
- Takao Hoshino, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Astra Zeneca
NONE
SOS-Attaque Cérébrale Association
None
NONE
NONE
NONE
NONE
NONE
NONE
- Shinichiro Uchiyama, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence K.S. Wong, MD,
AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, Sanofi, Otsuka
NONE
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Pfizer, Sanofi, Otsuka
Associate Editor, JNNP
NONE
NONE
NONE
NONE
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Pfizer, Sanofi, Otsuka
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Kazuo Kitagawa, MD,
(1) Amgen
NONE
None
(1) Journal of Atherothrombosis, Associate editor (2) Journal of Cerebral Blood Flow and Metabolisim, editorial board member
NONE
NONE
NONE
NONE
(1) Kyowa Kirin (2) Daiichi-Sankyo (3) Bayer
NONE
(1) Clinical procedure (Neurology and Stroke Center), 50% of effort
(1) Daiichi-Sankyo (2) Eisai (3) Beohringer Ingelheim (4) Dainippon Sumitomo
(1) Grants-in-Aid for Scientific Researchin Japan (C), 19K07968, cheif investigator, 2019-2021
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hugo Charles, BST,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Julien Labreuche, BST,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Philippa C. Lavallée, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Gregory W. Albers, MD,
iSchemaViewBiogenGenentech
NONE
iSchemaView
Stroke
RAPID software (brain imaging)
NONE
NONE
iSchemaView (commercial)Genetech (commercial)
NONE
NONE
NONE
NONE
NIH grants (U10NS086487 and U01NS092076) fromthe National Institute of Neurological Disorders and Stroke.
NONE
None
iSchemaView (1)
NONE
RAPID software, Stanford University
iSchemaView
NONE
NONE
- Louis R. Caplan, MD,
Advisory Boards - Lytics Lifecycle- Genentech for Activase 2008 data safety monitoring Aruba study no compensation in 2 yearsall these are uncompensated
NONE
None
Archives of Neurology - editorial board -2000-2019Stroke- editorial Board
NONE
Drislane, F.W., Benetar, M., Chang, B.S., Acosta, J.A.,Croom, J.E., Tarulli, A., Caplan, L.R.: Blueprints inNeurology, 2nd edition. Philadelphia: Lippincott Williams& Wilkins, 2006.- also 3,4,5th editionsStroke Syndromes 3rd Edition, Caplan LR, van Gijn (Eds) Cambridge University press, 2012Caplan LR, Caplan
NONE
NONE
Boehringer-Ingelheim, (none in 2 years) Bristol ?Meyer- Squibb ,(none in 2 years Sanofi Synthelabo,(none in 2 years Astra-Zenec, (none in 2 years)Otsuka Pharmaceuticals ( none in 2 years)
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Geoffrey A. Donnan, MD,
None
NONE
Pfizer, Bayer, Boehringer Ingelheim
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Australian National Health and Medical Research grants. Chief Investigator, 2012-2016, 2017-21
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- José M. Ferro, MD,
Advisory Board - Boehringer Ingelheim (BI) (2014-2019)
NONE
None
Serve as an editorial board member of Cerebrovascular Diseases and Stroke (1991-present)
NONE
Royalties from
Received honoraria from BI for a lecture (2014,2018)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Michael G. Hennerici, MD,
None
NONE
None
Cerebrovascular Dis, Editor J Neuroimaging, Ed BoardJ Clin Med, Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Carlos Molina, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Peter M. Rothwell, MD,
Bayer - Executive Committee of ARRIVE Trial - 2006 onwards;BMS - DSMB member on Phase-2 antithrombotic trial - 2018 onwards
NONE
I don't keep a record. Certainly had travel expenses paid by Sanofi-Aventis, Servier, Astra-Zeneca and Bayer in past. However, nothing relevant to this manuscript.
Editorial Board - Lancet Neurology, International Journal of Stroke
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- P. Gabriel Steg, MD,
ServierNovartis
NONE
Novo NordiskRegeneronSanofiBMS
Circulation, Senior Associate Editor 2018 to now
co-inventor of a patent on use of alirocumab to reduce cardiovascular risk. All royalties assigned to Sanofi
NONE
NONE
AstraZeneca: co chair THEMIS trialAmarin: steering committee REDUCE IT trialAmgen: consultingBMS: consultingBoehringer Ingelheim: Steering Committee REDUAL trialIdorsia: Steering Committee SOS AMI trialNovartis: Steering Committee PARADISE MI trialPfizer: Critical Event Committee VERTIS programSanofi: co chair ODYSSEY OUTCOMES trialServier: chair CLARIFY registry
NONE
NONE
NONE
Amarin, Bayer, Sanofi, Servier
Programme Investissement d'Avenir, French government, PI, 2017-2021
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre-Jean Touboul, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Éric Vicaut, MD,
(1)Pfizer (2)BMS
NONE
(1)BMS
NONE
NONE
NONE
NONE
(1)Pfizer (2) BMS (3) Daiichi Sankyo (4) Hexacath (5)Novartis (7) Abbott
NONE
NONE
NONE
(1) Pfizer (2) BMS
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Amarenco, MD;
Bristol Myers SquibbPfizerMerckAstra ZenecaSanofi-AventisBoehringer-IngelheimFibrogenKowaAmgen
NONE
Bristol Myers SquibbPfizerMerckAstra ZenecaSanofi-AventisBoehringer-IngelheimKowaAmgen
Stroke journal (Senio editor, Europe)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Sanofi-AventisBristol Myers SquibMerckAstra Zeneca
PI, TIAregistry.org registryPI, Treat Stroke to Target Trial, PHRC (french government) AOM-09002 and AOM-102181
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the TIA registry.org Investigators
- From the Department of Neurology and Stroke Center (T.H., H.C., J.L., P.C.L., P.-J.T., P.A.), Bichat Hospital, AP-HP and INSERM LVTS-U1148, DHU FIRE, Université Paris-Diderot, Sorbonne-Paris Cité, France; Center for Brain and Cerebral Vessels (S.U.), Sanno Hospital and Sanno Medical Center, International University of Health and Welfare, Tokyo, Japan; Department of Medicine and Therapeutics (L.K.S.W.), Chinese University of Hong Kong, Prince of Wales Hospital; Department of Neurology (T.H., K.K.), Tokyo Women's Medical University, Japan; Université Lille (J.L.), Centre Hospitalier Universitaire Lille, Équipe d'Accueil 2694-Santé Publique: Épidémiologie et Qualité des Soins, Lille, France; Stanford Stroke Center (G.W.A.), Department of Neurology and Neurological Sciences, Stanford University Medical Center, CA; Cerebrovascular Disease Service (L.R.C.), Beth Israel Deaconess Medical Center, Harvard University, Boston, MA; Melbourne Brain Centre (G.A.D.), Royal Melbourne Hospital, University of Melbourne, Parkville, Australia; Department of Neurosciences (J.M.F.), Service of Neurology, Hospital Santa Maria, University of Lisbon, Portugal; Department of Neurology (M.G.H.), Universitäts Medizin Mannheim, Heidelberg University, Germany; Stroke Unit, Department of Neurology (C.M.), Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Spain; Stroke Prevention Research Unit (P.M.R.), Nuffield Department of Clinical Neuroscience, University of Oxford, UK; Department of Cardiology (P.G.S.), Bichat Hospital, AP-HP, Paris, France; National Heart and Lung Institute Imperial College (P.G.S.), Institute of Cardiovascular Medicine and Science Royal Brompton Hospital, London, UK; Department of Biostatistics (É.V.), Université Paris-Diderot, Sorbonne-Paris Cité, Fernand Widal Hospital, AP-HP, Paris, France.
- Correspondence
Dr. Amarenco pierre.amarenco{at}aphp.fr
Article usage
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.